51 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
27419473	4	Neolignans from the Arils of Myristica fragrans as Potent Antagonists of CC Chemokine Receptor 3.	Kindai University
25497216	99	Rodent selectivity of piperidine-4-yl-1H-indoles, a series of CC chemokine receptor-3 (CCR3) antagonists: insights from a receptor model.	Boehringer Ingelheim Pharma
23142617	57	Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H1 antagonists. Part I.	Astrazeneca
23116889	88	Discovery and evolution of phenoxypiperidine hydroxyamide dual CCR3/H1 antagonists. Part II: optimising in vivo clearance.	Astrazeneca
23075267	85	Discovery and lead optimization of a novel series of CC chemokine receptor 1 (CCR1)-selective piperidine antagonists via parallel synthesis.	Bristol-Myers Squibb
22931505	69	Chemokine receptor antagonists.	National Heart and Lung Institute
23031591	90	The discovery of CCR3/H1 dual antagonists with reduced hERG risk.	Astrazeneca
23046963	23	Pyrrolidinyl phenylurea derivatives as novel CCR3 antagonists.	Toray Industries
23031649	4	The therapeutic journey of benzimidazoles: a review.	Punjabi University
23021991	153	Scaffold-hopping with zwitterionic CCR3 antagonists: identification and optimisation of a series with good potency and pharmacokinetics leading to the discovery of AZ12436092.	Astrazeneca
22749826	28	Discovery and structure-activity relationships of urea derivatives as potent and novel CCR3 antagonists.	Toray Industries
18752960	48	Design and synthesis of 6-fluoro-2-naphthyl derivatives as novel CCR3 antagonists with reduced CYP2D6 inhibition.	Astellas Pharma
17951061	20	Synthesis and structure-activity relationships of N-{1-[(6-fluoro-2-naphthyl)methyl]piperidin-4-yl}benzamide derivatives as novel CCR3 antagonists.	Astellas Pharma
18096386	131	From rigid cyclic templates to conformationally stabilized acyclic scaffolds. Part I: the discovery of CCR3 antagonist development candidate BMS-639623 with picomolar inhibition potency against eosinophil chemotaxis.	Bristol-Myers Squibb
16198561	99	Novel CCR1 antagonists with oral activity in the mouse collagen induced arthritis.	Novartis Institutes For Biomedical Research
14505678	21	Design and synthesis of novel CCR3 antagonists.	Roche Palo Alto
21940167	12	Design and synthesis of a library of chemokine antagonists.	Novartis Institutes of Biomedical Research
21341682	37	Discovery, optimization, and pharmacological characterization of novel heteroaroylphenylureas antagonists of C-C chemokine ligand 2 function.	Telik
19674898	31	Spiropiperidine CCR5 antagonists.	Roche Palo Alto
19620010	43	Synthesis, biological evaluation, and metabolic stability of acrylamide derivatives as novel CCR3 antagonists.	Astellas Pharma
19131247	42	Discovery of trisubstituted cyclohexanes as potent CC chemokine receptor 2 (CCR2) antagonists.	Bristol-Myers Squibb
19014885	32	Discovery of a potent, selective and orally bioavailable 3,9-diazaspiro[5.5]undeca-2-one CCR5 antagonist.	Roche Palo Alto
19010676	28	Urea based CCR3 antagonists employing a tetrahydro-1,3-oxazin-2-one spacer.	Bristol-Myers Squibb
18160284	46	From rigid cyclic templates to conformationally stabilized acyclic scaffolds. Part II: Acyclic replacements for the (3S)-3-benzylpiperidine in a series of potent CCR3 antagonists.	Bristol-Myers Squibb
17720492	107	Capped diaminopropionamide-glycine dipeptides are inhibitors of CC chemokine receptor 2 (CCR2).	Bristol-Myers Squibb
17532633	29	Pyrazolone methylamino piperidine derivatives as novel CCR3 antagonists.	Ucb Pharma
17418570	141	CC chemokine receptor-3 (CCR3) antagonists: improving the selectivity of DPC168 by reducing central ring lipophilicity.	Bristol-Myers Squibb Pharmaceutical Research Institute
16931001	93	2,4-Disubstituted piperidines as selective CC chemokine receptor 3 (CCR3) antagonists: synthesis and selectivity.	Bristol-Myers Squibb Pharmaceutical Research Institute
16698264	37	Discovery of 3,5-bis(trifluoromethyl)benzyl L-arylglycinamide based potent CCR2 antagonists.	Merck Research Laboratories
16539392	29	Highly potent and orally active CCR5 antagonists as anti-HIV-1 agents: synthesis and biological activities of 1-benzazocine derivatives containing a sulfoxide moiety.	Takeda Pharmaceutical
15908209	25	The synthesis of substituted bipiperidine amide compounds as CCR3 ligands: antagonists versus agonists.	Schering-Plough Research Institute
15771462	125	Discovery of CC chemokine receptor-3 (CCR3) antagonists with picomolar potency.	Pharmaceutical Research Institute
15743194	91	Novel ligands for the chemokine receptor-3 (CCR3): a receptor-modeling study based on 5D-QSAR.	Biographics Laboratory 3R
15713390	53	The synthesis of substituted bipiperidine amide compounds as CCR3 antagonists.	Schering-Plough Research Institute
15664858	36	N-Arylalkylpiperidine urea derivatives as CC chemokine receptor-3 (CCR3) antagonists.	Dbristol-Myers Squibb
15664834	31	Pyrrolidinohydroquinazolines--a novel class of CCR3 modulators.	Boehringer Ingelheim Pharma Gmbh And
15026042	50	Discovery of N-propylurea 3-benzylpiperidines as selective CC chemokine receptor-3 (CCR3) antagonists.	Bristol-Myers Squibb Pharmaceutical Research Institute
12166951	146	Discovery and structure-activity relationship of N-(ureidoalkyl)-benzyl-piperidines as potent small molecule CC chemokine receptor-3 (CCR3) antagonists.	Bristol-Myers Squibb
12067561	97	CCR3 antagonists: a potential new therapy for the treatment of asthma. Discovery and structure-activity relationships.	Bristol-Myers Squibb
11720852	51	Design, synthesis, and SAR of heterocycle-containing antagonists of the human CCR5 receptor for the treatment of HIV-1 infection.	Merck Research Laboratories
11720851	52	Discovery of human CCR5 antagonists containing hydantoins for the treatment of HIV-1 infection.	Merck Research Laboratories
11378374	39	Discovery of potent and selective phenylalanine derived CCR3 receptor antagonists. Part 2.	Smithkline Beecham Pharmaceuticals
11378373	35	Discovery of potent and selective phenylalanine derived CCR3 antagonists. Part 1.	Smithkline Beecham Pharmaceuticals
11354381	19	Discovery of a novel CCR3 selective antagonist.	Banyu Tsukuba Research Institute
11311066	76	Design, synthesis, and discovery of a novel CCR1 antagonist.	Banyu Tsukuba Research Institute In Collaboration With Merck Research Laboratories
11206474	51	Antagonists of the human CCR5 receptor as anti-HIV-1 agents. Part 2: structure-activity relationships for substituted 2-Aryl-1-[N-(methyl)-N-(phenylsulfonyl)amino]-4-(piperidin-1-yl)butanes.	Merck Research Laboratories
10821717	29	Discovery of novel, potent, and selective small-molecule CCR5 antagonists as anti-HIV-1 agents: synthesis and biological evaluation of anilide derivatives with a quaternary ammonium moiety.	Takeda Chemical Industries
29406702	128	Discovery of Novel 1-Cyclopentenyl-3-phenylureas as Selective, Brain Penetrant, and Orally Bioavailable CXCR2 Antagonists.	Gsk Pharmaceuticals R & D